CD19 and autoimmune disease: In addition, an in vitro study has shown that combining CD19 antibody with CD19 CAR-NK or CAR-T can enhance the serial killing capacity of these immune cells by facilitating rapid detachment of these CAR effector cells from target cells by reducing trogocytosis [224], further testifying the validity of combined B-cell depleting immunotherapy in treating autoimmune disease.